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R.J.Th.J. Welten,4 L.H.J.M. van den Akker,5 H.A.J.M. Kurvers,1,2 C.A. Bruggeman2,3
and P.J.E.H.M. Kitslaar1,21Department of Surgery, Maastricht University Hospital, 2Cardiovascular Research Institute of Maastricht
(CARIM), 3Department of Med. Microbiology, Maastricht University Hospital, Maastricht, 4Department of
Surgery, Atrium Medical Centre, Heerlen, and 5Department of Surgery, Maasland Hospital, Sittard,
The NetherlandsBackground. Sero-epidemiological and experimental studies suggest that Chlamydia pneumoniae infections play an
important role in the development of atherosclerosis. Clinical trials have shown contradictory results regarding the efficacy of
antibiotics to prevent atherosclerosis-related complications in patients with coronary artery disease. Our aim was to study
the effect of a short course of azithromycin on the incidence of cardiovascular events and peripheral vascular function in
patients with stable peripheral arterial disease (PAD).
Patients and methods. Five hundred and nine PAD-patients were randomised to receive either a 3-day course of
azithromycin (500 mg daily) or placebo, with 2 years of follow-up. C. pneumoniae serology was determined at baseline.
Clinical endpoints were death, coronary events (myocardial infarction, unstable angina, and/or coronary revascularization
procedures), cerebral events (stroke, TIA, and/or carotid endarterectomy) and peripheral arterial complications (increased
PAD-symptoms with decreased ankle-brachial index (ABPI, 0.1-point decrease after 12 months), and/or peripheral
revascularization procedures).
Results. Five hundred and nine patients (160 women) with an atherosclerotic risk factor profile were randomised, 257
patients to azithromycin and 252 to placebo. Four hundred and forty nine patients (88%) had intermittent claudication and
60 (12%) had critical limb ischemia. By 24-month follow up, 182 patients (36%) developed 252 complications (45 deaths, 34
coronary events, 34 cerebral events and 139 peripheral arterial complications). C. pneumoniae IgA-titres were associated
with the development of cardiovascular events. Nevertheless, the number of complications (131 in the azithromycin group
vs. 121 in the placebo group) and the number of patients that developed complications (98 (38%) in the azithromycin vs. 84
(33%) in the placebo group) was comparable in both treatment groups. Life table analysis showed no effect of azithromycin
on survival or ABPI.
Conclusion. A short-term course of azithromycin offers no benefits for survival or ankle pressure in PAD-patients.Keywords: Atherosclerosis; Peripheral vascular disease; Chlamydia pneumoniae; Azithromycin; Randomised clinical trial.Introduction
Recently it has become evident that atherosclerosis is
an inflammatory disease.1 Consequently, infections
triggering immune responses, may play an important
role in the initiation or propagation of atherosclerosis.ing author. Dr Tryfon Vainas, Department of Surgery,
niversity Hospital, P.O. Box 5800, 6202 AZ Maastricht,
nds.
: t.vainas@ah.unimaas.nl
0403+ 09 $35.00/0 q 2005 Elsevier Ltd. All rights reserAlready in the early 20th century, before the inflam-
matory nature of atherosclerosis became widely
accepted, it had been suggested that infections may
contribute to the development of atherosclerosis.2–4
However, it was not before 1978 that it had been
proven experimentally that infections may lead to the
development of atherosclerosis.5 Subsequently, it has
been observed that acute (respiratory tract) infections
were associated with acute coronary events,6,7 and
especially that Chlamydia pneumoniae infections were
associated with coronary artery disease.8 TheEur J Vasc Endovasc Surg 29, 403–411 (2005)
doi:10.1016/j.ejvs.2005.01.001, available online at http://www.sciencedirect.com onved.
T. Vainas et al.404identification of C. pneumoniae in the atherosclerotic
plaque further supported the notion that C. pneumoniae
infections may be associated with the development of
atheroslerosis.9 The infection hypothesis really gained
momentum when two groups independently reported
that antibiotics may prevent cardiovascular events in
patients with coronary artery disease.10,11 Since then,
antibiotic trials conducted throughout the world have
provided contradictory results regarding the efficacy
of antibiotics for prevention of atherosclerotic compli-
cations. Most of the studies showing favourable results
were of small sample size, included patients with
abdominal aortic aneurysms or peripheral arterial
disease, or used surrogate endpoints such as flow-
mediated dilation. In contrast, three larger studies of
patients with coronary artery disease demonstrated no
beneficial effect of antibiotics in the prevention of acute
coronary events and/or death.12–14
Peripheral arterial disease (PAD) represents a
manifestation of atherosclerosis affecting up to 20%
of primary care attendees.15 The systemic nature of
atherosclerosis is shown by the high prevalence of co-
existent coronary and cerebral arterial disease in these
patients.15 Therefore, PAD patients are a suitable
group in which to study the effect of interventions
altering the progression of atherosclerosis, both in
terms of clinically relevant events and in terms of
easily accessible surrogate hemodynamic endpoints
such as the ankle-brachial pressure index (ABPI).
C. pneumoniae is an obligate intracellular microbe
showing a tropism for macrophages. The antibiotic
azithromycin yields high intracellular macrophage
concentrations after a 3 day course, that 10 days after
the last dose still is in the bactericidal range (O
32 mg/l).16 Furthermore, compared to other macrolide
antibiotics, such as roxithromycin, azithromycin has a
better gastro-intestinal tolerability.17 Considering the
above, we tested the hypothesis that, in PAD patients,
a short course of azithromycin would reduce the
subsequent incidence of atherosclerotic events of the
coronary, cerebral and peripheral arterial circulation,
as well as on (changes in) ABPI.Patients and Methods
Patients with symptomatic peripheral arterial disease
(intermittent claudication or critical limb ischemia)
were recruited at the surgical clinics of a university
hospital and two affiliated teaching hospitals.
Inclusion and exclusion criteria are given in Table 1.
The study was approved by the medical ethics
committees of all participating centres and conformed
with the principles outlined in the declaration ofEur J Vasc Endovasc Surg Vol 29, April 2005Helsinki.18 All patients entered the study after giving
written informed consent.
The study was designed as a randomised, double-
blind, placebo controlled, secondary prevention trial
of a short course of azithromycin (3 days) in patients
with PAD. The hypothesis was that the azithromycin
treatment would lead to a clinically significant, i.e.
50% reduction of the combined event rate. In order to
calculate the required number of patients needed to
show this effect, the data reported by Dormandy et al.
were used.19 With an annual event rate of 15%, 204
patients in every treatment group were needed to
observe the desired effect after 2 years, with a power
(b) of 0.95 and a type I error (a) of 0.05. To ensure
sufficient events within 2 years target recruitment was
500 patients.
At inclusion patients underwent physical examin-
ation. The presence of atherosclerotic risk factors was
assessed and cardiac and cerebrovascular co-morbid-
ities were documented. The ABPI was measured in the
supine position after a 15-min rest period. The ankle
pressure was measured in the posterior tibial and
dorsal pedal artery. The highest ankle pressure was
used to determine the ABPI.
After the baseline clinical and hemodynamic
evaluation, venous blood was drawn and patients
were randomised to receive a 3-day course of
azithromycin (500 mg daily) or an identical looking
placebo. In order to assess drug tolerability and
compliance, patients were asked to keep a ‘treatment
logbook’. The randomisation list was computer gen-
erated in blocks of five and randomisation was
performed in six strata, i.e. three participating clinics
by two clinical presentations (claudication or critical
limb ischemia). Patients, attending surgeons and the
coordinating scientist were blind to the intervention.Outcomes
The primary endpoint was a composite of ‘all cause
mortality and/or any coronary/cerebral/peripheral
arterial event’. We selected all cause mortality rather
than cardiovascular mortality as part of the primary
outcome variable, as often the cause of death cannot be
established clearly for patients dying outside the
hospital.20
Coronary events included myocardial infarction
(defined by chest pain, elevated cardiac enzymes,
and/or new diagnostic q-waves in at least two
contiguous leads), de novo unstable angina pectoris
(defined by chest pain, supported by either ECG
changes suggestive of ischemia or elevated level of
cardiac enzymes, greater than normal but not
Table 1. Inclusion- and exclusion criteria
Inclusion criteria Symptomatic PAD
ABPI!0.9 or decrease of ankle pressure with 25 mmHg after standardized treadmill exercise
Exclusion criteria Recent antibiotic use (!3 months)
Recent vascular (coronary, cerebral, peripheral) event (!6 months)
Recent vascular (coronary, cerebral, peripheral) intervention (!12 months)
Renal failure
Liver failure
Life expectancy!2 years
Malignancy
Inflammatory co-morbidity
Azithromycin in PAD 405diagnostic for myocardial infarction), and/or any
coronary revascularization procedure (PTCA or cor-
onary artery bypass grafting, CABG). A cerebral event
was any stroke or transient ischemic attack, TIA
(diagnosis based on clinical symptoms and character-
istic changes on cerebral computed tomography
and/or magnetic resonance imaging). A peripheral
arterial event was defined as worse symptoms (e.g.
increased severity of ischaemic pain) that was
accompanied by either a decrease in ABPI of at least
0.1 and/or by any peripheral revascularization pro-
cedure (PTA or reconstructive vascular surgery). In
addition to these clinical endpoints, changes in ABPI
over a 12-month period were analysed. A change in
ABPI of at least 0.1 was considered significant
(significant increase or decrease).C. pneumoniae serology
C. pneumoniae IgA-titres were determined by a
commercially available enzyme immunoassay (Lab-
systems, Finland) as previously described.21 Titres
were calculated from optical density readings accord-
ing to the manufacturer’s instructions and were
expressed in enzyme immunounits (EIUs). Although
no consensus has been reached so far regarding the
definition of C. pneumoniae sero-positivity,22 patients
with an IgA-titre O16 EIUs were considered sero-
positive in view of previously published studies
showing an association between C. pneumoniae sero-
positivity and atherosclerosis using this cut off
point.23–25Statistics
The c2-test was used for analysis of dichotomous
variables and the Mann–Whitney U test for analysis of
continuous variables. Wilcoxon signed rank test was
used to compare average ABPI at inclusion and at 12
months. Kaplan–Meier with log-rank statistics was
used for the analysis of event free survivals in both
treatment groups. Analyses were carried out on anintention to treat basis. All statistics were performed
on SPSS 10.0 for windows software package.Results
Five hundred and nine patients were randomised. As
expected a high proportion of our patients had
(multiple) conventional cardiovascular risk factors
(Table 2). Efforts were made to assure that all patients
received best medical (secondary preventive) treat-
ment. This implies that all patients were given
antiplatelet therapy, that patients with untreated
hyperglycemia or hypertension were referred to a
physician for serum glucose and blood pressure
regulation, and that patients with cholesterol O
5 mmol/l were treated with statins. The randomis-
ation yielded two comparable groups (azithromycin
group:NZ257; placebo group:NZ252) with respect to
the prevalence of cardiovascular risk factors (Table 2),
severity of PAD (Table 3), type of vascular treatment at
inclusion and degree of vascular co-morbidity (Table
3), baseline ABPI (Table 3) and C. pneumoniae serology
(Table 4). Patients were followed for a median of 24
months (range: 1–44 months).
Among the patients, 88% suffered from intermittent
claudication and 12% had critical limb ischemia, i.e.
resting pain and/or ischemic tissue loss (Table 3). The
baseline treatment plan was conservative in the
majority of cases (Table 3). Approximately one third
of the patients were scheduled to undergo an early
intervention, either catheter based (18%) or vascular
surgery (14%). A significant proportion of patients
suffered from cardiovascular co-morbidities, i.e. 32%
had co-existent coronary artery disease, 15% had
cerebrovascular disease and 10% were diagnosed
with or had been treated for an abdominal aortic
aneurysm. The average (SD) ABPI was 0.63 (0.18). The
average (SD) C. pneumoniae IgA-titre was 28 (30) EIUs
and 52% of patients were considered sero-positive
(having an IgA O16 EIUs) (Table 4).
Azithromycin was well tolerated by the patients
and self-reported compliance was excellent.Eur J Vasc Endovasc Surg Vol 29, April 2005
Table 2. Patient characteristics
Total group Azithromycin group Placebo group P
N 509 (100%) 257 (50.4%) 252 (49.6%) NS
Average age (SD), years 64.9 (9.7) 64.4 (9.9) 65.5 (9.7) NS
Male 348 (68%) 178 (69%) 170 (67%) NS
Female 161 (32%) 79 (31%) 82 (33%) NS
Cardiovas. fam. history* 310 (61%) 148 (58%) 162 (64%) NS
Smoking† 400 (79%) 206 (80%) 194 (77%) NS
Dislipidemia‡ 412 (81%) 210 (82%) 202 (80%) NS
Hypertension§ 295 (58%) 149 (58%) 146 (58%) NS
Diabetes¶ 143 (28%) 77 (30%) 66 (26%) Ns
* First degree relative with first ischemic cardiovascular event before age of 70.
† Currently smoking or stopped!10 year ago.
‡ Fasting cholesterol levelO6.5 mmol/l and/or triglyceride levelO1.95 mmol/l and/or the use of antidislipidemic medication.
§ Systolic blood pressureO160 mmHg and/or diastolic blood pressureO95 mmHg and/or the use of antihypertensive medication.
¶ Fasting glucose levelO7 mmol/l and/or the use of antiglycemic medication/insulin.
T. Vainas et al.406Approximately 95% of patients completed the
assigned treatment, i.e., 242/257 (94%) azithromycin
treated patients and 242/252 (95%) placebo treated
patients. Fifteen patients in the azithromycin group
and 10 patients in the placebo group discontinued
treatment mainly due to (mild) gastro-intestinal
complaints (diarrhoea, nausea, vomiting, flatulence,
stomach-pain). One patient in the azithromycin group
developed a skin rash.Follow up, cardiovascular events and azithromycin
In total, 182 patients (36%) developed 252 events
during follow up (Table 5). Thirty-three patients (6%)
developed 34 coronary events, 33 patients (6%) had 34
cerebrovascular events, 108 patients (21%) developed
139 peripheral arterial events and 45 patients (9%)
died. Neither the total number of cardiovascular
complications, nor the number of patients developing
an event differed between groups. Ninety-eight
patients (38%) treated with azithromycin developedTable 3. Cardiovascular status of the PAD patients at inclusion
Total
Degree of PAD (Fontaine class)
Claudication (Fontaine II) 449 (88%)
Critical limb ischemia (Fontaine III/IV) 60 (12%)
Total 509 (100%)
Average (SD) ABPI 0.63 (0.18)
Vascular intervention plan at inclusion
Conservative 344 (68%)
Balloon angioplasty (PTA) 92 (18%)
Reconstructive vascular surgery 73 (14%)
Total 509 (100%)
Vascular co-morbidity
CAD 163 (32%)
CVD 76 (15%)
AAA 50 (10%)
Combined CAD&CVD 36 (7%)
This table shows the degree of PAD, ABPI, the planned vascular treatme
the study. CAD, coronary artery disease; CVD, cerebrovascular disease
Eur J Vasc Endovasc Surg Vol 29, April 2005131 complications vs. 84 patients (33%) developing 121
cardiovascular events in the placebo group (Mann–
Whitney U test for comparison of total number of
events, PZ0.37, and c2-test for comparison of fractions
of patients reaching the combined endpoint, PZ0.26).
In addition, the fraction of patients developing
multiple events did not differ between either group
(c2-test, PZ0.57). Cumulative freedom from the
combined endpoint (death and/or any cardiovascular
event, Fig. 1) or from death, coronary, cerebrovascular,
or peripheral event separately was not influenced by
azithromycin (Kaplan–Meier with log-rank test, PZ
0.32 for survival differences in the combined
endpoint).ABPI and azithromycin
The average (SD) ABPI at inclusion was 0.63 (0.18).
This increased significantly to 0.70 (0.21) in the total
group after 1 year (Wilcoxon signed rank test, PZ
0.001). This increase in ABPI resulted mainly fromAzithromycin Placebo P
227 (88%) 222 (88%) Ns
30 (12%) 30 (12%) Ns
257 (100%) 252 (100%) Ns
0.63 (0.18) 0.62 (0.18) Ns
178 (69%) 166 (66%) Ns
40 (16%) 52 (21%) Ns
39 (15%) 34 (13%) Ns
257 (100%) 252 (100%) Ns
79 (31%) 84 (33%) Ns
41 (16%) 35 (14%) Ns
24 (9%) 26 (10%) Ns
18 (7%) 18 (7%) Ns
nt and the cardiovascular co-morbidity of the patients at inclusion in
; AAA, abdominal aortic aneurysm.
Table 4. C. pneumoniae IgA-titres and sero-positivity
Entire population (NZ509) Azithromycin (NZ257) Placebo (NZ252) P
Average (SD) IgA, EIUs 27.6 (30.8) 26.6 (28.7) 28.7 (32.8) 0.86*
N (%) C. pneumoniae sero-positive 265 (52) 139 (54) 126 (50) 0.49†
* Mann–Whitney U test.
† c2-test.
Azithromycin in PAD 407interventions (PTA or surgery). For the patients who
did not undergo any intervention within the first year,
the ABPI increased slightly, though significantly from
0.66 to 0.68 (Wilcoxon signed rank test, PZ0.009).
Given the reproducibility of ABPI measurements this
difference may not reflect an actual clinical improve-
ment. In contrast, the ABPI increased from 0.58 (0.17)
to 0.74 (0.23) in those patients who had an intervention
within 1 year after randomisation. This difference is
both clinically and statistically significant (Wilcoxon
signed rank test, PZ0.001). Whether the patients had
undergone an intervention or not, azithromycin did
not affect (the change in) ABPI at 1 year (Mann–
Whitney U Test, PZ0.71) (Table 5). The number of
patients showing a significant increase or decrease in
ABPI (0.1) did not differ significantly between azi-
thromycin- and placebo-treated patients (c2-test, PZ
0.21). Exclusion of patients with critical limb ischemia
(12%) from the analyses did not alter any of the above
associations.C. pneumoniae serology and extent of atherosclerosis and
PAD
The mean C. pneumoniae IgA-titre and the prevalence
of C. pneumoniae sero-positivity (IgA O16 EIUs) were
comparable in the azithromycin and placebo group
(Table 4). C. pneumoniae serology was not related to
severity of peripheral arterial disease (Fontaine class
or ABPI) at inclusion. However, patients who reached
a cardiovascular (combined) endpoint (Mann–Whit-
ney U test, PZ0.02), and especially a peripheralTable 5. Follow up data regarding the effect of azithromycin on card
Azithromycin group
N events N (%) pa
Coronary events 19 19 (7)
Cerebral events 18 17 (7)
Peripheral events 74 58 (23)
Death 20 20 (8)
All events 131 98 (38)
Average (SD) ABPI at inclusion 0.64 (0.18)
Average (SD) ABPI at 12 months 0.71 (0.19)
Average (SD) change in ABPI in 12
months
0.07
Median (range) follow up (months) 24.3 (0–41)
* Mann–Whitney U test for comparison of number of events or avera
† c2-test for comparison of fraction of patients reaching events betwearterial endpoint (Mann–Whitney U test, PZ0.01)
had a higher average IgA-titre compared to patients
who remained free of events (Table 6). C. pneumoniae
IgA sero-positivity was related to the development of
the combined endpoint (c2-test, PZ0.03), and of
peripheral arterial events more specifically (c2-test,
PZ0.05) (Table 6).
Despite the association between C. pneumoniae
serology and the occurrence of events, azithromycin
treatment did not reduce the risk of any event in the
total patient group.Discussion
Our data shows that a short course of azithromycin
does not reduce the risk of death or cardiovascular
events in patients with lower limb ischemia secondary
to occlusive peripheral atherosclerotic disease, irre-
spective of their serological status. Furthermore,
azithromycin treatment did not affect the ABPI in
these patients.
A number of randomised clinical trials assessing the
effect of antibiotics on atherosclerosis related compli-
cations or biochemical and hemodynamic endpoints
have been published (Table 7). Generally, in those
studies reporting a benefit from antibiotics, a small
number of patients have been included or followed for
only a limited time, so that only a modest number of
events have been observed under antibiotic exposure.
Larger trials with longer follow up periods have, in
accordance with our data, unequivocally shown thatiovascular and hemodynamic endpoints
Placebo group P* P†
tients N events N (%) patients
15 14 (6) 0.41 0.40
16 16 (6) 0.75 0.76
65 50 (20) 0.46 0.45
25 25 (10) 0.40 0.40
121 84 (33) 0.37 0.26
0.62 (0.18) 0.61
0.70 (0.22) 0.73
0.08 0.71
24.9 (0–45) 0.28
ge follow up period between groups.
en groups.
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Fig. 1. Cumulative freedom from the primary (combined) endpoint (death and/or any cardiovascular event) in the
azithromycin (black curve) and placebo group (grey curve).
T. Vainas et al.408antibiotics have no effect in reducing the risk for
clinical cardiovascular endpoints.12–14,26 In total,
including the present study, 12,901 patients have
been included in the randomised clinical antibiotic
trials with clinical cardiovascular endpoints (Table 7).
The studies reporting beneficial effects of antibiotics
on cardiovascular risk prevention have included 1583
patients, and 858 of these were randomised to receive
the experimental treatment.11,27–30 In contrast, 11,318
patients were included and 5660 patients were
randomised to receive an antibiotic in the negative
studies.12–14,26,31,32 In order to demonstrate the poten-
tially beneficial effects of antibiotics on atherosclerosis
using a limited number of patients (and cardiovascularTable 6. Prevalence of C. pneumoniae IgA sero-positivity (IgA O16 E
relation to cardiovascular endpoints
% IgA sero-positivity
All patients (nZ509) 52
Reaching combined endpoint (nZ182) 59
Free of combined endpoint (nZ327) 49
Reaching coronary event (nZ33) 50
Free of coronary event (nZ476) 52
Reaching cerebral event (nZ32) 60
Free of cerebral event (nZ477) 51
Reaching PAD event (nZ108) 61
Free of PAD event (nZ401) 49
Death (nZ45) 59
Free of death (nZ464) 51
* Mann–Whitney U test.
† c2 test.
Eur J Vasc Endovasc Surg Vol 29, April 2005events), several authors have chosen to study surrogate
endpoints that might be more sensitive to the anti-
atherogenic effects of antibiotics, such as carotid intima
media thickness,31 basal NO production,33 flow-
mediated dilatation,34,35 aortic expansion rate,36,37
matrix metalloproteinase metabolism,38 or presence of
C. pneumoniae DNA in vascular tissue.39
The demonstration of (a lack of) beneficial effects in
cardiovascular event reduction by the clinical trials
does not necessarily (dis)prove the infectious concept
of atherosclerosis. Accruing sero-epidemiological,
histological, in vitro, and animal experimental data
strongly suggest that infections play a (modulatory)
role in atherogenesis in general40 and in theIUs) and average (SD) C. pneumoniae IgA-titre in the patients in
P* Average (SD) IgA-titre (EIUs) P†
28 (30)
0.03 32 (34) 0.02
25 (28)
0.83 29 (34) 0.69
28 (31)
0.36 27 (27) 0.49
28 (31)
0.05 36 (37) 0.01
25 (28)
0.34 32 (30) 0.26
27 (31)
Table 7. Overview of randomised clinical trials of antibiotics in cardiovascular disease
Trial/author Diagnosis Treatment Follow up
(months)
N Result
AB Duration Total AB PL
Gupta et al.11 CAD Azi 3–6 d 18 60 40 20 YCVE
ISAR-348 stent roxi 4 w 12 1010 506 504 Yrestenosis
CLARIFY49 ACS clari 3 mo 18 148 74 74 YCVE
STAMINA37 ACS azi 3 d 12 325 111 107 YCVE
amoxy 1 w 107
Wiesli et al.45 PAD roxi 4 w 20 40 20 20 YPAD events
ROXIS35 ACS roxi 30 d 6 202 102 100 ZCVE
ACADEMIC12 CAD azi 3 mo 24 302 150 152 ZCVE
ANTIBIO14 ACS roxi 6 w 12 872 433 439 ZCVE
WIZARD13 CAD azi 3 mo 24 7.722 3.866 3.856 ZCVE
AZACS24 ACS azi 5 d 24 1.439 716 723 ZCVE
Sander et al.25 CVD roxi 4 w 48 272 136 136 ZCVE
SPACE PAD azi 3d 24 509 257 252 ZCVE
N of patients in positive clinical endpoint trials 1.583 858 725
N of patients in negative clinical endpoint trials 11.318 5.660 5.658
N of patients in all clinical endpoint trials 12.901 6.518 6.383
AAA, abdominal aortic aneurysm; AB, antibiotic group; ACS, acute coronary syndromes; amoxy, amoxicylin; azi, azithromycin; CAD, stable
coronary artery disease; CEA, carotid endarterectomy; clari, clarithromycin; CVE, cardiovascular event; CVD, cerebrovascular disease; d,
days; doxi, doxicyclin; mo, months; PAD, peripheral arterial disease; PL, placebo group; roxi, roxithromycin; w, weeks; ‘Z’, no effect; ‘Y’,
reduced.
Azithromycin in PAD 409development of peripheral arterial disease in particu-
lar.41 In our study population, the baseline C.
pneumoniae serology was not related to the extent of
atherosclerotic disease in terms of clinical severity or
ABPI at inclusion in the study. However, we observed
an association between C. pneumoniae serology and
development of future cardiovascular events and
especially peripheral arterial events during follow
up. In spite of that, the 3-day azithromycin treatment
did not result in a significant reduction of events in
this population. In line with this findings, antibiotic
treatment has proven to have no effect on C.
pneumoniae titres in cardiovascular patients.28,31,32,36,42
The lack of beneficial effects from antibiotics in the
prevention of atherosclerosis-related complications
may be related to inadequate study medication
and/or sub-optimal patient selection. We chose
azithromycin as this was the most commonly used
antibiotic in the trials with cardiovascular endpoints.
Azithromycin has proven to be well tolerated and can
be used safely in patients with atherosclerotic dis-
ease.42 In vitro work suggested that vascular C.
pneumoniae strains were susceptible to azithromycin
as well as to roxithromycin and doxycyline.43 Instinc-
tively one would expect that higher doses of anti-
biotics or longer treatment duration should have been
more effective in reducing cardiovascular risk. Sur-
prisingly, benefit from azithromycin treatment has
been shown by studies with short course treatments
(3–6 days, total azithromycin dose varying between
1500 and 3000 mg),11,28 whereas trials with prolonged
azithromycin treatment regimes did not show any
beneficial effects.12,13 Irrespective of the duration of asingle antibiotic course, published data suggest that if
there is any effect, it may wear off with time. A
preliminary report of the ROXIS trial showed a
significant reduction of the primary endpoint (cardiac
ischaemic death, myocardial infarction, and severe
recurrent ischaemia) by roxithromycin at 31 days10
whereas this effect had worn off at 6 months.32
Similarly, roxithromycin seemed to reduce intima-
media thickness progression in patients with cerebro-
vascular disease during the first 2 years after treatment,
but this effectwas lost after 4 years.31 A temporary effect
of antibiotic treatment has also been suggested by the
dataof theWIZARDtrial showingareduceddeathorMI
risk at 6 months after randomisation but not after a
longer follow up.13 Bearing in mind that our study
populationwas too small to observe a sufficient number
of early events (i.e. within 6 months from randomis-
ation), our data did not support an early effect of
azithromycin on cardiovascular events that waned over
time. Antibiotics may have only a transient effect, as
patientsmay contract recurrentC. pneumoniae infections
or suffer from C. pneumoniae reactivation, after the
microbe has been forced into a latent state, instead of
being eliminated by the antibiotic treatment. Indeed, in
an in vitro continuous infectionmodel of epithelial cells,
prolonged azithromycin treatment reduced but did not
completely eliminate C. pneumoniae.44 Furthermore, C.
pneumoniae carried within circulating monocytes has
shown to be refractory to standard anti-chlamydial
treatments such as azithromycin.45 It remains to be seen
whether longer-duration antibiotic treatments or
repeated antibiotic treatment cycles would result in a
significant cardiovascular risk reduction.Eur J Vasc Endovasc Surg Vol 29, April 2005
T. Vainas et al.410In addition to C. pneumoniae, several other patho-
gens have been implicated in atherogenesis such as
Helicobacter pylori,46 cytomegalovirus,47 and herpes
simplex virus.48 In fact, it seems that the total pathogen
burden more than an individual micro-organism is
associated with increased risk of developing cardio-
vascular disease.41,49 Thus treatments aimed at C.
pneumoniae may not cover all contributory pathogens,
explaining the failure of current antibiotic regimes.
A critical issue of the randomised clinical trials is
the selection of patients. Several authors have chosen
to include only C. pneumoniae sero-positive patients.11–
13,27 High C. pneumoniae antibody titres have been
associated with presence of atherosclerosis and the
development of cardiovascular events. However,
antibiotics do not seem to affect C. pneumoniae
titres.28,31,32,36,42 This matter is further complicated by
the fact that no uniform criteria for C. pneumoniae sero-
positivity have been formulated.22 Since the preva-
lence of C. pneumoniae antibodies in the general
population is high, we chose to include patients
regardless of their serological status.50
Atherosclerotic disease status at entry may be
important for the outcome of antibiotic intervention
trials. Experimental data suggests that C. pneumoniae
may promote all stages of atherosclerosis develop-
ment, i.e. plaque growth, rupture, thrombosis and
neointimal formation after vascular intervention.51 In
previously published trials, patients with acute cor-
onary syndromes (i.e. acute myocardial infarction,
unstable angina or non-q-wave infarcts), stable ather-
osclerotic disease of the coronary, cerebral and
peripheral arteries, or after coronary stent placement
have been included, and treated with variable success
with antibiotics (Table 7). Only neointimal formation
after stent-placement seems to be inhibited by roxi-
thromycin, but this result has come from only one
study and needs to be verified by others. We attempted
to assess the influence of antibiotics on the progression
of atherosclerosis in patients with PAD. To avoid the
influence of tissue destruction following acute vascu-
lar events or surgery on inflammatory responses
affecting atherosclerosis we included only patients
with stable PAD free from recent events and
interventions.
In summary, this is currently the largest study
assessing the effect of azithromycin on patients with
peripheral arterial disease. Although C. pneumoniae
serology was related to the development of cardiovas-
cular events, the 3-day azithromycin treatment did not
reduce the prevalence of cardiovascular complication,
and has, therefore, no place in the secondary preven-
tion of patients with stable peripheral arterial disease.Eur J Vasc Endovasc Surg Vol 29, April 2005Acknowledgements
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